Bioethics News

Breakthrough Gene Technology Attracts Investors Amid Patent Dispute

Deals continue to be signed for gene-editing tool called Crispr-Cas9

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.